Cellebrite DI Ltd. (NASDAQ:CLBT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $21.40.

Several equities research analysts have recently commented on the company. DA Davidson assumed coverage on Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price for the company. Needham & Company LLC cut their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th.

Insiders Place Their Bets

In other Cellebrite DI news, CFO David Barter sold 41,734 shares of the company’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at approximately $5,474,507.22. This represents a 11.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Thomas E. Hogan sold 103,188 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the completion of the transaction, the chief executive officer directly owned 590,777 shares in the company, valued at $9,310,645.52. This trade represents a 14.87% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 158,191 shares of company stock valued at $2,479,438. 5.70% of the stock is currently owned by insiders.

Institutional Trading of Cellebrite DI

Institutional investors have recently bought and sold shares of the business. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its position in shares of Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares during the last quarter. CWM LLC boosted its position in shares of Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after purchasing an additional 889 shares during the last quarter. SkyView Investment Advisors LLC grew its stake in shares of Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after purchasing an additional 970 shares during the period. Alamea Verwaltungs GmbH grew its stake in shares of Cellebrite DI by 4.3% during the fourth quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock worth $444,000 after purchasing an additional 1,018 shares during the period. Finally, Pacer Advisors Inc. increased its holdings in Cellebrite DI by 45.1% in the fourth quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock valued at $72,000 after purchasing an additional 1,238 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Price Performance

CLBT stock opened at $15.83 on Friday. The company has a 50 day moving average price of $13.98 and a 200 day moving average price of $14.42. Cellebrite DI has a fifty-two week low of $11.02 and a fifty-two week high of $19.98. The stock has a market capitalization of $3.95 billion, a PE ratio of 56.54, a price-to-earnings-growth ratio of 1.96 and a beta of 1.17.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.